Overview
- An international consortium published the Nature Medicine paper on July 28 after analyzing genetic data from more than 2.5 million people, including about 55,000 diagnosed with fibromyalgia, and reported 26 genomic regions that alter disease risk.
- The study found that genes tied to risk are more active in nerve cells than in immune cells, supporting the idea that fibromyalgia arises from altered pain-processing in the nervous system rather than primary autoimmunity.
- Researchers detected shared genetic links between fibromyalgia and other conditions, including a variant in the HTT region tied to Huntington’s disease and overlaps with irritable bowel syndrome, chronic low-back pain, and PTSD, which points to possible drug-repurposing targets.
- The authors emphasize these findings provide a biological roadmap for mechanistic work and drug development but do not support genetic tests for diagnosis or immediate new treatments, so clinical care still relies on individualized, symptomatic approaches.
- Fibromyalgia affects a large and often under-recognized patient population, commonly causes widespread pain, fatigue and cognitive symptoms, and the study’s next steps to track specific brain pathways and test candidate drugs will determine how this genetic evidence changes care.